We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POCTs Urgently Needed in Resource-Limited Countries

By LabMedica International staff writers
Posted on 20 Jun 2012
In resource-limited settings, the impact of diagnostic tests that can be provided at the immediate point-of-care (a point-of-care test or POCT) is potentially even greater, because the alternative to a POCT may be no diagnostic support at all.

Easy-to-use, inexpensive tests to diagnose infectious diseases are urgently needed in resource-limited settings. More...
A new report based on an American Academy of Microbiology colloquium (September, 2011; Washington DC, USA), describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most.

Point-of-care diagnostics (POCTs) bypass the need for sophisticated laboratory systems by leveraging new technologies to diagnose infectious diseases and other health concerns at the bedside, or point-of-care. Diagnostics account for 2% of the cost of health care, yet can affect 60%-70% of treatment decisions. In resource limited areas where advanced laboratory services are not available, access to POCTs may be the difference between making a treatment decision that is informed by an accurate diagnosis versus one that is ineffective or even harmful.

Despite the urgent need for POCTs, deploying them in resource-limited settings can be difficult. "POCTs are developed by researchers and engineers and implemented by a separate group of public health professionals at a local level. There are so many variables that can make or break the effectiveness of any test, and so often the scientists and engineers developing the test are not aware of them." said Keith Klugman, who chaired the colloquium. "POCTs that perform well in testing may not function 'on the ground' in resource-limited areas, where there may not be running water, electricity, or trained personnel to administer the test."

Recognizing the need to connect the scientists and engineers developing the POCTs with the health care workers implementing them, the American Academy of Microbiology convened the colloquium to discuss how to develop POCTs that can be effectively integrated into resource-limited settings. The participants discussed which tests were needed most urgently, features that should be incorporated in the design of the test to make it more effective in the field, and how collaborations between communities could foster an environment of success for new POCTs.

The resulting report makes recommendations in several areas. It details a list of POCTs that would make the biggest impact, for example, tests to detect drug resistance, or effectively monitor viral load in HIV patients. The report describes qualities needed such as minimal power requirements, simple interfaces, and integrated instructions on use and quality control protocols. Finally, it recommends changes in how POCTs are regulated, approved, and brought to market to help foster a more conducive environment for POCT development.

Related Links:

American Academy of Microbiology




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.